Ketamine

   Ketamine therapy, recognized for its rapid antidepressant effects, holds promise in treating conditions like treatment-resistant depression, anxiety disorders, and PTSD. Under the supervision of healthcare professionals, sessions aim to elicit transformative personal experiences. However, it is not without risks, including short-term side effects and potential long-term neurological changes if used improperly.

​

   With roots in both historical healing methods and modern clinical research, ketamine therapy targets the brain's N-methyl-D-aspartate (NMDA) receptors, resulting in rapid antidepressant effects within hours, unlike traditional antidepressants. It's crucial to acknowledge the potential risks associated with ketamine therapy, such as short-term side effects like disorientation and confusion, as well as possible long-term neurological changes and the risk of addiction. Misuse of ketamine, particularly in recreational settings, can exacerbate these risks, potentially leading to physical dependence and cognitive issues.

​

   Originally introduced as a battlefield anesthetic in 1970, ketamine gained popularity as "Special K," a club drug. Recently, there has been a surge in injected ketamine-assisted therapy, supported by research indicating breakthroughs among patients with hard-to-treat mental health problems. However, the regulatory gaps surrounding ketamine have also fueled its abuse. Ketamine can be addictive, and heavy, long-term use can result in significant health problems, including irreversible urinary tract damage. The Food and Drug Administration (FDA) has issued warnings about the dangers of treating psychiatric disorders with compounded versions of ketamine, highlighting the risks of unsupervised use.

​

Informed decision-making is essential in ketamine therapy. Patients should be fully informed about the potential benefits and risks, and sessions should be conducted under strict clinical supervision. The ethical implications of emerging therapies like ketamine underscore the importance of careful consideration, ongoing research, and responsible clinical practice in mental health care.

​

Drozdz, Sandra J, at al., “Ketamine Assisted Psychotherapy: A Systematic Narrative 

Review of the Literature”. (PubMed Central),(June 15, 2022) Accessed March

31, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207256/

 

Hodgman-Korth, Madeline, “Ketamine Short and Long Term Effects of Ketamine”.

(American Addiction Centers), (June 23, 2023) Accessed March 31, 2024. 

https://americanaddictioncenters.org/ketamine-abuse/ketamine-side-effects

 

Christopher, Paul P, “Ethical Issues in Emerging Treatments for 

NeuroPsychiatric Disorders” (PubMed Central), (July 16, 2018) Accessed April 

12, 2024.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493096/

 

Stone, Judy, “Hennepin Ketamine Study Raises Questions About Ethics 

And Consent” (Forbes), (July 26, 2018) Accessed April 12, 2024. 

https://www.forbes.com/sites/judystone/2018/07/26/hennepin-

ketamine-study-raises-questions-about-ethics-and-consent/?sh=3f6662805be7

 

Jacobs, Andrew, “F.D.A Issues Warning Over Misuse of Ketamine” (The

 New York Times), (October 11, 2023) Accessed April 12, 2024. 

https://www.nytimes.com/2023/10/11/health/fda-ketamine-warning.html

 

Strous, JurriaanF.M, at al., “Brain Changes Associated With Long-Term Ketamine

Abuse, A Systematic Review” (PubMed Central), (March 18, 2022) Accessed April 12, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972190/

​